Results 11 to 20 of about 81,753 (307)
Journal of Experimental & Clinical Cancer Research, 2021 Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis.
Mitsuhito Hirano +19 more
doaj +1 more source
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]
, 2013 Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Bartsch, Georg +6 more
core +8 more sources
Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective [PDF]
Metabolites, 2021 Histone deacetylases (HDACs) are epigenetic enzymes that play a central role in gene regulation and are sensitive to the metabolic state of the cell. The cross talk between metabolism and histone acetylation impacts numerous biological processes including development and immune function.
Jacob King +2 more
openaire +3 more sources
Toll-like signaling and the cytokine IL-6 regulate histone deacetylase dependent neuronal survival. [PDF]
PLoS ONE, 2012 Histone deacetylase (HDAC) proteins have a role in promoting neuronal survival in vitro, but the mechanism underlying this function has not been identified. Here we provide evidence that components of the neuronal microenvironment, including non-neuronal
Nicole Forgione, Vincent Tropepe
doaj +1 more source
Cells, 2021 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a dismal prognosis. Here, we show how an inhibition of de novo dNTP synthesis by the ribonucleotide reductase (RNR) inhibitor hydroxyurea and an inhibition of epigenetic ...
Alexandra Nguyen +5 more
doaj +1 more source
Biological Research, 2020 Background Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their effect on tumor treatment has been disappointing mainly due to the acquisition of HDAC inhibitor resistance.
Won Chan Hwang +5 more
doaj +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
, 2016 Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi +130 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Rational Combinations Using HDAC Inhibitors [PDF]
Clinical Cancer Research, 2009 Abstract In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as ...
Bots, Michael, Johnstone, Ricky W.
openaire +2 more sources
Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Breast cancer is an important women’s malignancy with high cancer-related deaths worldwide. Drug resistance lowers the treatment efficacy in this malignancy. This study aimed to explore the underlying mechanisms of histone deacetylase (HDAC)
Lingyan Wang, Yukai Xu, Chunhui Gao
doaj +1 more source